TY - JOUR
T1 - bcl-2/bax mRNA expression ratio as prognostic factor in low-grade urinary bladder cancer
AU - Gazzaniga, Paola
AU - Gradilone, Angela
AU - Vercillo, Roberta
AU - Gandini, Orietta
AU - Silvestri, Ida
AU - Napolitano, Maria
AU - Albonici, Loredana
AU - Vincenzoni, Andrea
AU - Gallucci, Michele
AU - Frati, Luigi
AU - Aglianó, Anna Maria
PY - 1996/4/22
Y1 - 1996/4/22
N2 - Apoptotic cell death represents an important mechanism for the precise regulation of cell numbers, and a defence mechanism against tumoral cells. bcl-2 and bax genes are known to be involved in the control of apoptotic pathways; in particular, the ratio between bcl-2 and bax represents a cell rheostat that is able to predict a cell's response toward life or death to an apoptotic stimulus. In the present study we investigated the role of bcl-2 and bax gene expression in a panel of 37 low-grade tumours of the urinary bladder, and correlated the expression of these genes to the prognosis of patients in a follow-up of more than one year. We found that levels of bax expression higher than bcl-2 in bladder tumours well correlates to a better outcome for patients. Early relapses are much more frequently observed in those patients whose tumours express more bcl-2 than bax mRNA. We conclude that the bcl-2/bax expression ratio may be considered as a marker for disease progression in low grade bladder tumours, independently of clinical staging and histological grading.
AB - Apoptotic cell death represents an important mechanism for the precise regulation of cell numbers, and a defence mechanism against tumoral cells. bcl-2 and bax genes are known to be involved in the control of apoptotic pathways; in particular, the ratio between bcl-2 and bax represents a cell rheostat that is able to predict a cell's response toward life or death to an apoptotic stimulus. In the present study we investigated the role of bcl-2 and bax gene expression in a panel of 37 low-grade tumours of the urinary bladder, and correlated the expression of these genes to the prognosis of patients in a follow-up of more than one year. We found that levels of bax expression higher than bcl-2 in bladder tumours well correlates to a better outcome for patients. Early relapses are much more frequently observed in those patients whose tumours express more bcl-2 than bax mRNA. We conclude that the bcl-2/bax expression ratio may be considered as a marker for disease progression in low grade bladder tumours, independently of clinical staging and histological grading.
UR - http://www.scopus.com/inward/record.url?scp=15844367830&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=15844367830&partnerID=8YFLogxK
U2 - 10.1002/(SICI)1097-0215(19960422)69:2<100::AID-IJC5>3.0.CO;2-4
DO - 10.1002/(SICI)1097-0215(19960422)69:2<100::AID-IJC5>3.0.CO;2-4
M3 - Article
C2 - 8608975
AN - SCOPUS:15844367830
SN - 0020-7136
VL - 69
SP - 100
EP - 104
JO - International Journal of Cancer
JF - International Journal of Cancer
IS - 2
ER -